Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole – LH 21
- 1 August 2006
- journal article
- Published by Elsevier in Neuropharmacology
- Vol. 51 (2), 358-366
- https://doi.org/10.1016/j.neuropharm.2006.03.029
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Anxiolytic-Like Properties of the Anandamide Transport Inhibitor AM404Neuropsychopharmacology, 2006
- Clinical trials update and cumulative meta‐analyses from the American College of Cardiology: WATCH, SCD‐HeFT, DINAMIT, CASINO, INSPIRE, STRATUS‐US, RIO‐Lipids and cardiac resynchronisation therapy in heart failureEuropean Journal of Heart Failure, 2004
- Corticotropin-Releasing Hormone (CRH) mRNA Expression in Rat Central Amygdala in Cannabinoid Tolerance and Withdrawal: Evidence for an Allostatic Shift?Neuropsychopharmacology, 2003
- The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesisJCI Insight, 2003
- High throughput artificial membrane permeability assay for blood–brain barrierEuropean Journal of Medicinal Chemistry, 2003
- A Peripheral Mechanism for CB1 Cannabinoid Receptor-Dependent Modulation of FeedingJournal of Neuroscience, 2002
- Reversal of Dopamine D2Receptor Responses by an Anandamide Transport InhibitorJournal of Neuroscience, 2000
- REDUCTION OF VOLUNTARY ETHANOL INTAKE IN ETHANOL-PREFERRING sP RATS BY THE CANNABINOID ANTAGONIST SR-141716Alcohol and Alcoholism, 1998
- Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptorsPsychopharmacology, 1997
- Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid ReceptorScience, 1992